Third dose of Covid-19 vaccine benefits dialysis patients

In some patients, the immune system responds poorly to the second vaccination dose. This changes with the third shot.

Researchers studied the immune response of dialysis patients after two resp. three immunisation rounds against Covid-19. Twenty of the 23 participants benefited from a third dose of the vaccine. The results have been published online in a preliminary version in the journal “Kidney International” on 4 October 2021. The study was carried out jointly by the Centre for Translational Medicine of the Medical Clinic I of the Marien Hospital Herne, University Hospital of Ruhr-Universität Bochum (RUB), the RUB Department for Molecular and Medical Virology, the Dialysis Centre Schwerte and other partners in Germany and Switzerland.

New tests provide insights into the state of the immune system

Just like diseases, vaccines cause the body to form an immunological memory. This memory can prevent a second infection or illness caused by the same pathogen.

"Put simply, specific immunity is based on antibodies that prevent infection and on immune cells that can kill infected cells," explains Professor Nina Babel, head of the Centre for Translational Medicine specialized in immunology. With her colleagues, she has developed a technique that allows insight into the state of the immune system. To this end, the researchers determine in a test tube, so to speak, whether a person has functioning antibodies and immune cells against a certain pathogen.

Weaker immune response in dialysis patients

Dialysis patients have a weaker immune response than healthy people. "Some of our patients form either no vaccine-specific antibodies at all or very few following Sars-Cov-2 immunization," says Dr. Okan Cinkilic, nephrologist and head of the dialysis center in Schwerte. However, it is precisely this group of chronically ill people who contract severe cases of Covid-19. Moreover, it is not known how the immune system of dialysis patients reacts to virus variants such as the Delta variant. The team set out to determine whether patients could benefit from a third vaccination against the coronavirus.

The fact that renal patients need a stronger vaccination stimulus in order to develop a sufficient vaccination response is nothing new."

Professor Timm Westhoff, Director, Medical Department I, Marien Hospital Herne

This is well-known, for example, with regard to hepatitis B (HBV). Dialysis patients with missing or low hepatitis B antibody levels are boosted by HBV vaccine at regular intervals.

Better vaccination response after the third dose

In the current study, the research team examined 23 dialysis patients who had presented a reduced vaccination response after a second inoculation with an mRNA vaccine against Covid-19. All of them received a third dose. Twenty of them developed a high antibody titre and a killer cell response against the Sars-Cov-2 coronavirus.

The research team also studied 25 patients whose immune systems had already produced high titers of antibodies and killer cells after a second shot. "Interestingly, despite being high-responder after the second dose, their immune response was lower than the vaccination response of patients who did not respond to two doses and required the third one - even against the Delta variant," says Timm Westhoff.

"These results are clinically relevant," as Okan Cinkilic sums up the findings. The third vaccination round could bring benefit not only for patients who presented a reduced vaccination response or no response at all after two doses, but also for patients with a good antibody response after two shots. "Consequently, our data support the recently published recommendation of the Standing Committee on Vaccination, which recommends a third vaccination dose for people with reduced immunity, including dialysis patients," says Okan Cinkilic.

Source:
Journal reference:

Stervbo, U., et al. (2021) Improved cellular and humoral immunity upon a second BNT162b2 and mRNA-1273 boost in prime-boost vaccination no/low responders with end-stage renal disease. Kidney International. doi.org/10.1016/j.kint.2021.09.015.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Limited impact of prenatal COVID-19 exposure on child neurodevelopmental outcomes